Ask about this productRelated genes to: VDBP antibody
- Gene:
- GC NIH gene
- Name:
- GC vitamin D binding protein
- Previous symbol:
- -
- Synonyms:
- DBP, VDBP, hDBP
- Chromosome:
- 4q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-01-25
Related products to: VDBP antibody
Related articles to: VDBP antibody
- BackgroundThe International Headache Society has proposed new treatment goals for migraine prevention in real world, as a way to set higher standards of care. This study provides the first assessment of the proportion of individuals achieving them after 6 months of migraine-specific treatment with anti-CGRP monoclonal antibodies (MAbs).MethodsThis was a prospective, real-world, European multicenter study, including adults with migraine treated with anti-CGRP MAbs (EUREkA cohort). We assessed the proportions of individuals in each treatment goal category-migraine freedom (no monthly migraine days [MMD]); optimal control (< 4 MMD), modest control (4-6 MMD); insufficient control (>6 MMD)-after 6 months of treatment. We also assessed the proportion of individuals with ≥50% reduction in MMD in the insufficient control group.ResultsOf the 5818 individuals in the EUREkA cohort, 4963 had 6 months data. Of these, 82.3% (4086/4963) were females and the median age was 48.0 [40.0-55.0] years. At baseline, the median monthly headache days [MHD] and MMD were 20.0 [13.3-28.0] and 15.0 [10.0-20.0], respectively. All participants were classified as having insufficient headache control (>6 MMD) at baseline. At month 6, 6.9% (342/4963) had migraine freedom, 22.9% (1137/4963) optimal control, 24.6% (1223/4963) modest control and 45.6% (2261/4963) insufficient control. In the insufficient control group, 27.1% (613/2261) had ≥50% reduction in MMD.ConclusionsHigh standards of care, defined as optimal disease control or even migraine freedom, are achieved in real-world settings with anti-CGRP MAbs in approximately 30% of individuals with a high migraine burden. These findings highlight the need to expand global access to these treatments. Future studies should explore whether initiating migraine-specific preventive treatments earlier could further reduce residual migraine days in responders, enabling a larger proportion of patients to achieve optimal disease control. - Source: PubMed
Publication date: 2026/06/19
Caronna EdoardoMas-de-Les-Valls RutEgeo GabriellaVázquez Manuel MillánCastellanos Candela NievesMembrilla Javier AVaghi GloriaRodríguez-Montolio JoanaFabra Neus FabregatCaballero Francisco SánchezJaimes AlexMuñoz-Vendrell AlbertOliveira RenatoGárate GabrielOsorio Yesica GonzálezGuisado-Alonso DanielOrnello RaffaeleThunstedt CemFernández-Lázaro IrisSánchez-Soblechero AntonioHusøy Andreas KattemVicente Beatriz NunesBasedau HaukeRiesco Pérez Nuria PilarPina Belen FloresFernandes CatarinaAndrés-López AlbertoMartins-Silva ElisaBudrewicz SławomirArlanzón Pablo RosCaetano AndréGallardo Victor JoséGómez-Dabó LauraTorres-Ferrús MartaAlpuente AliciaTorelli PaolaAurilia CinziaZapata SilvanaPérez Raquel LamasRuiz Castrillo Maria JoséIcco Roberto DeSances GraziaBroadhurst SarahOng Hui ChingWinstanley JedAranceta SonsolesZubizarreta Izaro KortazarUrabayen Amalia EcheverriaGarcía Andrea GómezCampoy SergioMarques InêsParreira ElsaGonzález-Quintanilla VicenteGuerrero-Peral Ángel LuisMiró IsabelPeris-Subiza JuliaCaponnetto ValeriaStraube AndreasGonzalez-Martinez AliciaQuintas SoniaSánchez-Del-Río MargaritaTronvik ErlingPérez Begoña VenegasDurán Agustin OterinoRodrigues MiguelRamos Ana FriesEsteban Yago VaamondeCevoli SabinaColombo BrunoTrimboli MicheleFrediani Fabiod'Onofrio FlorindoAguggia MarcoSalerno AntonioCarnevale AntonioZucco MaurizioAlbanese MariaFinocchi CinziaRanieri AngeloZoroddu FrancescoAutunno MassimoSanahuja JordiCabral GonçaloBlasco Isabel BeltránWaliszewska-Prosół MartaPereira LilianaLayos-Romero AlmudenaLuzeiro IsabelDorado LauraÁlvarez Escudero Maria RocioMay ArneLópez-Bravo AlbaMartins Isabel PavãoSundal ChristinaIrimia PabloRos Alberto LozanoGago-Veiga Ana BeatrizJuanes Fernando VelascoRuscheweyh RuthSacco SimonaCuadrado-Godia ElisaGarcía-Azorín DavidPascual JulioGil-Gouveia RaquelHuerta-Villanueva MarianoRodriguez-Vico JaimeRomero Javier VigueraObach VictorSantos-Lasaosa SoniaGhadiri-Sani MonaTassorelli CristinaDíaz-de-Terán JavierInsa Samuel DíazOria Carmen GonzálezBarbanti PieroPozo-Rosich Patricia - Infectious haematopoietic necrosis virus (IHNV) causes devastating economic losses in salmonid aquaculture and effective control measures are urgently needed. This study investigates the anti-IHNV potential of postbiotics derived from Lactiplantibacillus plantarum. The crude postbiotic extract (PBP20o) and a neutralized version (PBP20a) were evaluated for cytotoxicity and antiviral activity in epithelioma papulosum cyprini (EPC) cells. Both extracts exhibited a safe concentration threshold of 1.15 μgmL. Remarkably, treatment with PBP20o and PBP20a at this non-cytotoxic concentration reduced IHNV titers by 0.82 log₁₀TCID₅₀/ml (84.9%) and 0.46 log₁₀TCID₅₀/ml (65.3%), respectively. The enhanced efficacy of the acidic extract might suggest a dual mechanism involving direct acid-mediated viral inactivation combined with the action of pH-stable bioactive metabolites. GC-MS identified three potential antiviral compounds, including such as trans-cinnamic acid (RT = 33.688, A% = 0.39), pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl) (RT = 48.516, A% = 13.54) and hexadecanamide (RT = 56.226, A% = 3.11) from L. plantarum postbiotic. This study identifies L. plantarum postbiotics as a novel and promising source of antiviral compounds, offering a potential alternative strategy for mitigating IHNV outbreaks in aquaculture while ensuring biosafety for the target host and end consumers. - Source: PubMed
Publication date: 2026/06/19
Lal Mohammad Tamrin MohamadRinggit GilbertWong Zy CheeLim Leong SengChing Fui FuiAl Zamzami Ilham MisbakudinJaziri Abdul AzizAziz Muhamad AfiqSaito HiroakiSano Motohiko - The optimal second-line therapy for advanced gastric/gastroesophageal junction cancer (GC/GEJC) following progression on first-line immuno-chemotherapy remains undefined. This study aimed to compare the efficacy and safety of continuing an immune checkpoint inhibitor beyond progression (CIBP) versus switching to a non-ICI regimen (non-CIBP). - Source: PubMed
Publication date: 2026/06/03
Wang GuangxiLu XiaonanWang YunmeiWang XiangWang RuoxuanJia Jinyu - Kidney transplantation is the only curative treatment for end-stage kidney disease, providing markedly improved outcomes over dialysis. In search of optimized long-term outcomes, recent studies have demonstrated alterations in the metabolic state of kidney transplant recipients (KTRs) may contribute to chronic graft outcomes. Here, we sought to benchmark metabolic perturbations associated with the post-transplant state using a set of extensively characterized kidney transplant donors as healthy control. - Source: PubMed
Publication date: 2026/06/03
Shehab Naser B NLammers-Jannink Kim C MRiphagen Margriet HEskandari Siawosh KAzzi Jamil Rde Borst Martin HBunte KerstinBakker Stephan J LHeiner-Fokkema M Rebecca - This study evaluated the quality and trustworthiness of large language model (LLM)-generated scientific and plain language summaries (PLS) from clinical oncology literature, focusing on faithfulness (absence of hallucinations), relevance, and readability. - Source: PubMed
Publication date: 2026/06/16
Stenzl ArnulfRogers EamonnAnaniadou SophiaWang YanshanArmstrong Andrew JSboner AndreaCacciamani GiovanniSchijvenaars Bob J AAhmed Kausar RiazThomsen HannaWiemken TimothyCampello AntonioSternberg Cora N